Wednesday, February 18, 2026 2/18/2026

In vivo mechanisms of Mycobacterium tuberculosis control and susceptibility

Award Number: F32HL158250
ORGANIZATION: NATIONAL HEART, LUNG, & BLOOD INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: FELLOWSHIP/SCHOLARSHIP/STUDENT LOANS
PERIOD OF PERFORMANCE START DATE: 04/01/2022
PERIOD OF PERFORMANCE END DATE: 11/30/2024

Group Awards By:

View Award Description

In vivo mechanisms of Mycobacterium tuberculosis control and susceptibility - Project Summary Mycobacterium tuberculosis (Mtb) infects the lungs causing 1.6 million deaths a year. The only vaccine approved for tuberculosis has limited efficacy. Additionally, antibiotic treatment requires six months, but can require two or more years for multi-drug resistant strains that are becoming more prevalent. Therefore, development of a host-directed therapeutic strategy that directly targets the Mtb reservoir would dramatically impact human health. I propose to identify novel innate immune factors that protect against Mtb infection in vivo, which could be the basis of such a therapeutic approach. Specific Aims: During Mtb infection, inflammatory cytokines like IL-1 stimulate non-infected cells to produce factors that enhance anti-bacterial activity of Mtb-bearing cells. While IL-1 is critical for protection against Mtb, its mechanism of action is unknown. Aim 1) We have identified IL-1 sensing cells in Mtb-infected lungs and IL-1-induced genes expressed by these cells. I will test whether natural killer T 17 cells, one of the IL-1 sensing populations, provides protection against Mtb. Additionally, I will determine which IL-1-induced genes act directly on Mtb infected macrophages in vivo to confer the protective effect of IL-1. Aim 2) Neutrophils are detrimental in Mtb- susceptible mouse strains and neutrophilia positively correlates with bacterial burden and mortality in humans. However, it is unclear how neutrophils interfere with the host response to Mtb. We have previously shown that IL-1 receptor antagonist (IL-1Ra) is an immunosuppressive molecule that limits Mtb control in a susceptible mouse strain. As IL-1Ra is highly expressed by neutrophils, I will determine whether neutrophils inhibit the protective response against Mtb through their production of IL-1Ra and whether this immunosuppressive function is conserved across multiple Mtb susceptible strains. Additionally, I will determine whether neutrophils exploit other immunosuppressive pathways, like IL-18 signaling inhibition and PD-1, to hinder the productive immune response to Mtb. Study Design: I will define how communication between non-infected and infected cells leads to control of tuberculosis infection by generating mixed bone marrow chimeras. These experiments will test the in vivo relevance of IL-1-driven gene expression for candidates identified in our single cell RNA- sequencing dataset of Mtb-infected lungs. Additionally, I will leverage our single cell RNA-sequencing dataset to determine how neutrophils inhibit control of the infection in Mtb-sensitive mouse strains. Potential Impact: The identification of protective and inhibitory regulators of Mtb control can serve as the basis for host-directed therapies to treat Mtb infection, which will be a major advance for the field.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = -$22,988 )
2025	2024	REGENTS OF THE UNIVERSITY OF CALIFORNIA, THE	1608 4TH ST STE 201	BERKELEY	CA	94710	ALAMEDA	USA	Lung Diseases Research	000	3	11/29/2024	NON-COMPETING CONTINUATION	-$22,988
														Subtotal = -$22,988

Issue Date FY: 2024 ( Subtotal = $84,364 )
2024	2024	REGENTS OF THE UNIVERSITY OF CALIFORNIA, THE	1608 4TH ST STE 201	BERKELEY	CA	94710	ALAMEDA	USA	Lung Diseases Research	001	3	8/29/2024	NON-COMPETING CONTINUATION	$5,812
2024	2024	REGENTS OF THE UNIVERSITY OF CALIFORNIA, THE	1608 4TH ST STE 201	BERKELEY	CA	94710	ALAMEDA	USA	Lung Diseases Research	000	3	4/2/2024	NON-COMPETING CONTINUATION	$78,552
														Subtotal = $84,364

Issue Date FY: 2023 ( Subtotal = $76,272 )
2023	2023	REGENTS OF THE UNIVERSITY OF CALIFORNIA, THE	1608 4TH ST STE 201	BERKELEY	CA	94710	ALAMEDA	USA	Lung Diseases Research	000	2	3/15/2023	NON-COMPETING CONTINUATION	$76,272
														Subtotal = $76,272

Issue Date FY: 2022 ( Subtotal = $72,302 )
2022	2022	REGENTS OF THE UNIVERSITY OF CALIFORNIA, THE	1608 4TH ST STE 220	BERKELEY	CA	94710	ALAMEDA	USA	Lung Diseases Research	000	1	12/15/2021	NEW	$71,062
2022	2022	REGENTS OF THE UNIVERSITY OF CALIFORNIA, THE	1608 4TH ST STE 201	BERKELEY	CA	94710	ALAMEDA	USA	Lung Diseases Research	001	1	12/15/2021	NEW	$0
2022	2022	REGENTS OF THE UNIVERSITY OF CALIFORNIA, THE	1608 4TH ST STE 201	BERKELEY	CA	94710	ALAMEDA	USA	Lung Diseases Research	002	1	6/24/2022	NEW	$1,240
														Subtotal = $72,302

Grand Total All Awards = $209,950

Top

All Categories

About

Search

Reports

Data Submission

Award Information

In vivo mechanisms of Mycobacterium tuberculosis control and susceptibility

Award Number: F32HL158250

ORGANIZATION: NATIONAL HEART, LUNG, & BLOOD INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: FELLOWSHIP/SCHOLARSHIP/STUDENT LOANS

PERIOD OF PERFORMANCE START DATE: 04/01/2022

PERIOD OF PERFORMANCE END DATE: 11/30/2024

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer